Hong Yingying, Zhang Jianyun, Zhang Heyu, Li Xuefen, Qu Jiafei, Zhai Jiemei, Zhang Lei, Chen Feng, Li Tiejun
Department of Oral Pathology, Peking University School and Hospital of Stomatology, Beijing, China.
Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, China.
J Bone Miner Res. 2016 Jul;31(7):1413-28. doi: 10.1002/jbmr.2815. Epub 2016 Mar 12.
Nevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant disorder characterized by bone and skin abnormalities and a predisposition to various tumors. Keratocystic odontogenic tumors (KCOTs), which are common tumors of the jaw that cause extensive damage to the jawbone, are usually accompanied with NBCCS. Germline PTCH1 mutations in NBCCS tumorigenesis have been frequently studied; however, little is known regarding the pathogenesis of bone abnormalities in this disease. This study sought to investigate the mechanism underlying heterozygous PTCH1 mutation-mediated abnormal bone metabolism in patients with NBCCS. Stromal cells were isolated from the fibrous capsules of patients with NBCCS-associated or non-syndromic keratocystic odontogenic tumors and non-syndromic tumor stromal cells without PTCH1 mutations served as controls. Germline PTCH1 heterozygous mutations were confirmed in all NBCCS samples and differential protein expression was identified using tandem mass tag-labeled proteomics analysis. Our findings revealed that osteonectin/SPARC expression was significantly downregulated in syndromic stromal cells compared with non-syndromic stromal cells. SPARC expression was even lower in stromal cells carrying PTCH1 protein truncation mutations. PTCH1 siRNA transfection demonstrated that SPARC downregulation correlates with decreased PTCH1 expression. Furthermore, exogenous SPARC promoted osteogenic differentiation of syndromic stromal cells with enhanced development of calcium nodules. In addition, bone mineral density tests showed that patients with NBCCS exhibit weak bone mass compared with sex- and age-matched controls. This study indicates that germline PTCH1 heterozygous mutations play a major role in bone metabolism in patients with NBCCS, in particular in those with PTCH1 protein truncation mutations. SPARC may represent an important downstream modulator of PTCH1 mediation of bone metabolism. Thus, bone mineral density monitoring is critical for patients with NBCCS for prevention of osteoporosis. In addition, surgical procedures on syndromic-associated KCOTs should be performed with consideration of the weaker bone mass in such patients. © 2016 American Society for Bone and Mineral Research.
痣样基底细胞癌综合征(NBCCS)是一种常染色体显性疾病,其特征为骨骼和皮肤异常以及易患多种肿瘤。牙源性角化囊性肿瘤(KCOTs)是常见的颌骨肿瘤,会对颌骨造成广泛损害,通常与NBCCS相关。NBCCS肿瘤发生过程中的种系PTCH1突变已得到广泛研究;然而,对于该疾病中骨骼异常的发病机制知之甚少。本研究旨在探究NBCCS患者中杂合性PTCH1突变介导的骨代谢异常的潜在机制。从与NBCCS相关或非综合征性牙源性角化囊性肿瘤的纤维囊中分离出基质细胞,未发生PTCH1突变的非综合征性肿瘤基质细胞作为对照。在所有NBCCS样本中均证实存在种系PTCH1杂合突变,并使用串联质谱标签标记的蛋白质组学分析鉴定差异蛋白表达。我们的研究结果显示,与非综合征性基质细胞相比,综合征性基质细胞中骨连接蛋白/富含半胱氨酸的酸性分泌蛋白(osteonectin/SPARC)表达显著下调。携带PTCH1蛋白截短突变的基质细胞中SPARC表达更低。PTCH1小干扰RNA转染表明,SPARC下调与PTCH1表达降低相关。此外,外源性SPARC促进了综合征性基质细胞的成骨分化,并增强了钙结节的形成。此外,骨密度测试显示,与性别和年龄匹配的对照组相比,NBCCS患者的骨量较弱。本研究表明,种系PTCH1杂合突变在NBCCS患者的骨代谢中起主要作用,尤其是在那些具有PTCH1蛋白截短突变的患者中。SPARC可能是PTCH1介导骨代谢的重要下游调节因子。因此,骨密度监测对于NBCCS患者预防骨质疏松至关重要。此外,对于与综合征相关的KCOTs进行手术时,应考虑到此类患者骨量较弱的情况。© 2016美国骨与矿物质研究学会